Clin Endosc.  2012 Jun;45(2):155-160. 10.5946/ce.2012.45.2.155.

Extended Spectrum-beta-Lactamase or Carbapenemase Producing Bacteria Isolated from Patients with Acute Cholangitis

• Goo JC
• Seong MH
• Shim YK
• Lee HS
• Han JH
• Shin KS
• Choi JW
• Youn SJ
• Park SM

• KMID: 2048854
• DOI: http://doi.org/10.5946/ce.2012.45.2.155

Abstract

BACKGROUND/AIMS
This study assessed the antibiotic resistance organisms isolated from the blood and bile of acute cholangitis and evaluated risk factors associated with them and their impact on clinical outcomes.
METHODS
The identities and antibiotic resistance profiles of bacteria isolated from 433 cases of acute cholangitis from 346 patients were analyzed. Risk factors and the outcomes of patients infected with them were assessed.
RESULTS
Microorganisms were isolated from 266 of 419 blood cultures and 256 of 260 bile cultures. Isolates from bile and blood were identical in 71% of the cases. A total of 20 extended spectrum-beta-lactamase (ESBL)-producers and 4 carbapenemase-producing organisms were isolated from blood, and 34 ESBL-producers and 13 carbapenemase-producers were isolated from bile. Sixty-four (14.8%) cases were infected with any one of these bacteria isolated from blood or bile. Risk factors associated with them in blood were nosocomial infection and prior biliary intervention. In bile, indwelling biliary device was a risk factor associated with them. Antibiotic-resistant bacteria were associated with mortality, independent of other prognostic factors.
CONCLUSIONS
ESBL or carbapenemase-producing bacteria were frequently isolated in acute cholangitis patients especially with prior biliary intervention and nosocomial infection. Isolation of antibiotic-resistant bacteria was an independent risk factor of mortality.

Keyword

Acute cholangitis; Bile culture; Blood culture; Microbial drug resistance

MeSH Terms

Bacteria
Bacterial Proteins
beta-Lactamases
Bile
Cholangitis
Cross Infection
Drug Resistance, Microbial
Humans
Risk Factors
Bacterial Proteins
beta-Lactamases

Reference

1. Sung JY, Leung JW, Shaffer EA, Lam K, Olson ME, Costerton JW. Ascending infection of the biliary tract after surgical sphincterotomy and biliary stenting. J Gastroenterol Hepatol. 1992; 7:240–245. PMID: 1611012.

2. Bornman PC, van Beljon JI, Krige JE. Management of cholangitis. J Hepatobiliary Pancreat Surg. 2003; 10:406–414. PMID: 14714159.

3. Rerknimitr R, Fogel EL, Kalayci C, Esber E, Lehman GA, Sherman S. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. Gastrointest Endosc. 2002; 56:885–889. PMID: 12447303.

4. Choi SH, Lee JE, Park SJ, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother. 2008; 52:995–1000. PMID: 18086837.

5. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005; 56:52–59. PMID: 15917288.

6. Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008; 168:1897–1902. PMID: 18809817.

7. Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect. 2008; 14(Suppl 1):159–165. PMID: 18154540.

8. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007; 51:1987–1994. PMID: 17387156.

9. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007; 60:1124–1130. PMID: 17884829.

10. Heo JH, Lee JH, Lee MY, et al. Bacterial identification in bile and blood of patients with acute cholangitis from benign and malignant bile duct obstruction. Korean J Gastroenterol. 2002; 40:53–59.

11. Flores C, Maguilnik I, Hadlich E, Goldani LZ. Microbiology of choledochal bile in patients with choledocholithiasis admitted to a tertiary hospital. J Gastroenterol Hepatol. 2003; 18:333–336. PMID: 12603536.

12. Englesbe MJ, Dawes LG. Resistant pathogens in biliary obstruction: importance of cultures to guide antibiotic therapy. HPB (Oxford). 2005; 7:144–148. PMID: 18333179.

13. Melzer M, Toner R, Lacey S, Bettany E, Rait G. Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes. Postgrad Med J. 2007; 83:773–776. PMID: 18057178.

14. Demirbağ AE, Karademir A, Parlak E, et al. Multidrug resistance of isolated microorganisms in occluded bile duct stents. Turk J Gastroenterol. 2007; 18:33–40. PMID: 17450493.

15. Bae WK, Moon YS, Kim JH, et al. Microbiologic study of the bile culture and antimicrobial susceptibility in patients with biliary tract infection. Korean J Gastroenterol. 2008; 51:248–254. PMID: 18516004.

16. Wada K, Takada T, Kawarada Y, et al. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg. 2007; 14:52–58. PMID: 17252297.

17. Wikler MA. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Sixteenth Informational Supplement. 2006. Wayne: Clinical and Laboratory Standards Institute.

18. Sung JY, Costerton JW, Shaffer EA. Defense system in the biliary tract against bacterial infection. Dig Dis Sci. 1992; 37:689–696. PMID: 1563308.

19. Negm AA, Schott A, Vonberg RP, et al. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointest Endosc. 2010; 72:284–291. PMID: 20541201.

20. Tanaka A, Takada T, Kawarada Y, et al. Antimicrobial therapy for acute cholangitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg. 2007; 14:59–67. PMID: 17252298.

21. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother. 2009; 64(Suppl 1):i3–i10. PMID: 19675017.

22. Guembe M, Cercenado E, Alcalá L, Marín M, Insa R, Bouza E. Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003-2007. Rev Esp Quimioter. 2008; 21:166–173. PMID: 18792817.

23. Jeon MH, Choi SH, Kwak YG, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn Microbiol Infect Dis. 2008; 62:402–406. PMID: 18993012.

24. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect. 2009; 73:345–354. PMID: 19596491.

25. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007; 60:913–920. PMID: 17848376.